Valneva SE ADR

Yahoo Finance • 6 days ago

Jefferies Reiterates Buy Rating on Valneva (VALN) After Phase 3 Data

Valneva SE (NASDAQ:VALN) is one of the 8 Most Oversold Strong Buy-Rated Stocks to Invest In. On March 23, 2026, Jefferies reiterated a Buy rating and $15 price target on Valneva SE (NASDAQ:VALN) following topline results from the Phase 3... Full story

Yahoo Finance • 21 days ago

Pfizer Lyme Vaccine Data Adds New Angle To Vaccine Portfolio Story

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Pfizer and Valneva reported Phase 3 results for their Lyme disease vaccine candidate, with over... Full story

Yahoo Finance • 21 days ago

Valneva Plunges As Lyme Vaccine Misses Key Goal In Phase 3 Trial; Shows More Than 70% Efficacy

(RTTNews) - Valneva SE (VALN) saw its stock drop sharply, even as the company and partner Pfizer announced that their Lyme disease vaccine candidate demonstrated more than 70% efficacy in a large Phase 3 study. Lyme disease, spread throug... Full story

Yahoo Finance • 21 days ago

Traders Digest Signs of Easing Middle East Tensions as US Equity Futures Rise Pre-Bell

US equity futures were up ahead of Monday's opening bell after President Donald Trump said he has or PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 21 days ago

Pfizer et Valneva annoncent que le candidat vaccin contre la maladie de Lyme démontre une forte efficacité dans l’essai de Phase 3 VALOR

Le candidat vaccin PF-07307405 (LB6V) a démontré une efficacité de plus de 70 % dans la prévention de la maladie de Lyme chez les personnes âgées de cinq ans et plus.Le candidat vaccin a été bien toléré, sans problème de sécurité identifié... Full story

Yahoo Finance • 26 days ago

Valneva SE (INRLF) Full Year 2025 Earnings Call Highlights: Strategic Advances Amid Financial ...

This article first appeared on GuruFocus. Release Date: March 18, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Valneva SE (INRLF) reported total revenues exce... Full story

Yahoo Finance • 26 days ago

Valneva reports FY results; gives FY26 outlook

* Valneva press release [https://seekingalpha.com/pr/20441902-valneva-reports-full-year-2025-audited-consolidated-financial-results] (VALN [https://seekingalpha.com/symbol/VALN]): FY Revenue of €174.7M (+3.0% Y/Y), including €157.9 milli... Full story

Yahoo Finance • 26 days ago

Valneva Reports Full Year 2025 Audited Consolidated Financial Results

Total revenues of €174.7 million in line with guidance, including €157.9 million in product sales Strong year-end cash position of €109.7 million, with enhanced financial flexibility following successful debt refinancing and a 21% reductio... Full story

Yahoo Finance • 26 days ago

Valneva publie ses résultats financiers audités et consolidés pour l’exercice 2025

Chiffre d’affaires de 174,7 millions d’euros, conforme aux prévisions, dont 157,9 millions de ventes de produits Solide position de trésorerie de 109,7 millions d’euros et flexibilité financière renforcée suite au refinancement réussi de... Full story

Yahoo Finance • 26 days ago

Valneva gibt die konsolidierten geprüften Finanzergebnisse für das Gesamtjahr 2025 bekannt

Der Gesamtumsatz von 174,7 Millionen Euro entspricht den Prognosen, davon 157,9 Millionen Euro aus Produktverkäufen Starke Liquiditätsposition zum Jahresende von 109,7 Millionen Euro, verbesserte finanzielle Flexibilität nach erfolgreiche... Full story

Yahoo Finance • last month

Valneva to Participate in Upcoming Investor Conferences

VALNEVA Lyon (France), March 2, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced its senior management will present and meet with investors at upcoming investor conferences in the United... Full story

Yahoo Finance • 5 months ago

Valneva to Further Consolidate its Operations in France 

French operations to be concentrated at its Lyon site Final consolidation of R&D in Vienna Saint-Herblain (France), November26, 2025– Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced a strategic initiative to optimize its or... Full story

Yahoo Finance • 5 months ago

Valneva va consolider ses activités en France

· Les activités françaises seront concentrées sur le site de Lyon · Consolidation de la R&D à Vienne Saint-Herblain (France), le 26 novembre 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) a annoncé aujourd'hui une initiative strat... Full story

Yahoo Finance • 5 months ago

Valneva Announces Positive Final Phase 2 Results for Lyme Disease Vaccine Candidate

Antibody levels remained well above baseline across all six serotypes and age groups sixth month after third yearly booster doseNo safety concerns observed in any age group by an independent Data Monitoring Committee (DMC)Results confirm b... Full story

Yahoo Finance • 5 months ago

Valneva annonce des résultats finaux positifs de Phase 2 pour son candidat vaccin contre la maladie de Lyme

Les taux d'anticorps sont restés supérieurs à leur niveau initial pour les six sérotypes et dans toutes les tranches d’âge six mois après la dernière injection des trois doses de rappel Aucun problème de sécurité n’a été observé dans tout... Full story

Yahoo Finance • 5 months ago

Valneva Reports Nine-Month 2025 Financial Results and Provides Corporate Updates

Total revenues of €127.0 million compared to €116.6 million in the first nine months of 2024Cash and cash equivalents of €143.5 million at end of September 2025Financial flexibility enhanced with successful debt refinancing in October 2025... Full story

Yahoo Finance • 5 months ago

Valneva publie ses résultats financiers des neuf premiers mois de 2025 et fait un point sur ses activités  

Chiffre d’affaires de 127,0 millions d’euros contre 116,6 millions d’euros sur les neuf premiers mois de 2024Trésorerie de 143,5 millions d’euros à fin septembre 2025Flexibilité financière accrue grâce au succès du refinancement de la dett... Full story

Yahoo Finance • 5 months ago

Valneva gibt Finanzergebnisse für die ersten neun Monate 2025 bekannt und informiert über Unternehmensentwicklungen

Gesamtumsatz von 127,0 Millionen Euro gegenüber 116,6 Millionen Euro in den ersten neun Monaten des Jahres 2024Liquide Mittel in Höhe von 143,5 Millionen Euro per Ende September 2025Finanzielle Flexibilität durch erfolgreiche Refinanzierun... Full story

Yahoo Finance • 5 months ago

Pre-Market Earnings Report for November 20, 2025 : WMT, NTES, J, VIPS, ROAD, MMS, BBWI, WMG, VNET, ATKR, ZIM, VALN

The following companies are expected to report earnings prior to market open on 11/20/2025. Visit our Earnings Calendar for a full list of expected earnings releases. Walmart Inc. (WMT)is reporting for the quarter ending October 31, 20... Full story

Yahoo Finance • 6 months ago

Valneva to Present and Hold Investor Meetings at Upcoming U.S. and European Healthcare Conferences

Saint-Herblain (France), October 27, 2025 –Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that its senior management will present and participate in 1-on-1 meetings with institutional investors... Full story